How Neurotouch Effectively Addresses ADA Guidelines
If you have diabetes, Neuropathy should be on your radar. This is a complication that causes nerve damage throughout your body. If left untreated, it has the potential to cause infection and can lead to amputation of the affected area. The most common type of neuropathy is peripheral neuropathy. It affects the nerves in the hands, feet, legs, and arms. It generally tends to start in both feet at once.
The American Diabetes Association (ADA), a non-profit organization that aims to lead the fight against the consequences of diabetes, recently issued guidelines stressing the importance of early diagnosis which involves regular screening, patient assessments, lifestyle and management strategies, as well as an evidence-based approach, with clinical validation for effective neuropathy screening.
Villgro’s healthcare portfolio incubatee Yostra has been dedicatedly involved in developing innovative screening technology for neuropathy screening. Yostra’s FDA-registered product named NEURO TOUCH aligns with these guidelines seamlessly. It offers comprehensive screening capabilities, including Monofilament Testing, Vibration Perception Test, and Hot and Cold Perception Tests.
The device has been clinically validated at renowned institutions, ensuring its reliability and effectiveness in neuropathy screening.
Here’s how Neurotouch effectively addresses ADA Guidelines:
Early and Regular Assessments (ADA Recommendations 12.17 & 12.18): The ADA advises regular assessments for DPN. NEURO TOUCH is designed for this purpose, offering comprehensive screening capabilities, including Monofilament Testing (for 10-g monofilament as recommended), Vibration Perception Test, and Hot and Cold Perception Tests. These features address the ADA’s call for thorough and ongoing patient assessment.
Identification of At-Risk Patients: NEURO TOUCH’s ability to conduct various tests aids in identifying patients at risk for foot ulcerations and amputations, aligning with the ADA’s emphasis on preventive care.
Recognition of Asymptomatic Cases: The ADA notes that up to 50% of DPN may be asymptomatic. NEURO TOUCH’s sensitive screening tools are essential in detecting such cases, and preventing complications such as diabetic foot ulcers (DFUs) and amputations.
Supporting Lifestyle and Management Strategies (References 43–45): Studies cited by the ADA suggest the importance of managing lifestyle factors in controlling DPN. NEURO TOUCH, as part of a comprehensive diabetes care plan, supports these strategies by facilitating early diagnosis and ongoing monitoring.
Clinical Validation and Evidence-Based Practice: With the ADA’s emphasis on evidence-based approaches, NEURO TOUCH has been clinically validated at renowned institutions, ensuring its reliability and effectiveness in neuropathy screening.
The team at Yostra understands the critical importance of aligning their products and practices with ADA standards to ensure the best care for patients with diabetes.
